FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jerome Schentag

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Physiology

Living Beings

Co-author Network

Publications

TOP 3
Scott V Monte; Jerome J Schentag; Chang Ling Sia; Joseph A Caruana; Husam Ghanim; Kelly Korzeniewski; Paresh Dandona
Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus.
Scott V Monte; Jerome J Schentag; Martin H Adelman; Joseph A Paladino
Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Scott V Monte; Jerome J Schentag; Martin H Adelman; Joseph A Paladino
Glucose supply and insulin demand dynamics of antidiabetic agents.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jerome Schentag (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Scott V Monte; Jerome J Schentag; Chang Ling Sia; Joseph A Caruana; Husam Ghanim; Kelly Korzeniewski; Paresh Dandona
Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus.
Surgery 2012;151(4):587-93.
2010: Scott V Monte; Jerome J Schentag; Martin H Adelman; Joseph A Paladino
Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Journal of diabetes science and technology 2010;4(2):382-90.
2010: Scott V Monte; Jerome J Schentag; Martin H Adelman; Joseph A Paladino
Glucose supply and insulin demand dynamics of antidiabetic agents.
Journal of diabetes science and technology 2010;4(2):365-81.
2009: Thomas M File; Scott V Monte; Jerome J Schentag; Joseph A Paladino; keith klugman; Bruce Lavin; Victor Yu; Mendel E Singer; Martin H Adelman
A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
International journal of antimicrobial agents 2009;33(1):58-64.
2008: Thomas M File; Jerome J Schentag
What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47 Suppl 3():S157-65.
2008: Joseph A Paladino; Jenna L Sunderlin; Mendel E Singer; Martin H Adelman; Jerome J Schentag
Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2008;65(12):1154-9.
2008: Scott V Monte; Nicole M Paolini; Erin M Slazak; Jerome J Schentag; Joseph A Paladino
Costs of treating lower respiratory tract infections.
The American journal of managed care 2008;14(4):190-6.
2008: Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
International journal of antimicrobial agents 2008;31(4):345-51.
2008: Joseph A Paladino; Jerome J Schentag
The economics of Clostridium difficile-associated disease for providers and payers.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(4):505-6.
2008: Gary A Noskin; Robert J Rubin; Jerome J Schentag; Jan A J W Kluytmans; Edwin C Hedblom; Cassie Jacobson; Maartje Smulders; Eric Gemmen; Murtuza Bharmal
Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals .
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2008;29(1):16-24.
2008: Sungmin Kiem; Jerome J Schentag
Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.
Antimicrobial agents and chemotherapy 2008;52(1):24-36.
2007: Gary A Noskin; Robert J Rubin; Jerome J Schentag; Jan A J W Kluytmans; Edwin C Hedblom; Cassie Jacobson; Maartje Smulders; Eric Gemmen; Murtuza Bharmal
National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(9):1132-40.
2007: Jerome J Schentag; keith klugman; Victor L Yu; Martin H Adelman; Gregory J Wilton; Christine C Chiou; Manish Patel; Bruce Lavin; Joseph A Paladino
Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study.
International journal of antimicrobial agents 2007;30(3):264-9.
2007: Joseph A Paladino; Jenna L Sunderlin; Martin H Adelman; Mendel E Singer; Jerome J Schentag
Observations on vancomycin use in U.S. hospitals.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2007;64(15):1633-41.
2007: Pamela A Moise; George Sakoulas; Alan Forrest; Jerome J Schentag
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.
Antimicrobial agents and chemotherapy 2007;51(7):2582-6.
2007: Jerome J Schentag; George Hill; Tom Chu; craig rayner
Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.
Journal of clinical pharmacology 2007;47(6):689-96.
2007: Joseph A Paladino; David A Eubanks; Martin H Adelman; Jerome J Schentag
Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
Journal of the American Geriatrics Society 2007;55(5):651-7.
2007: Joseph A Paladino; Martin H Adelman; Jerome J Schentag; Paul B Iannini
Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.
PharmacoEconomics 2007;25(8):677-83.
2006: Jaclyn M LeBlanc; Joseph F Dasta; Maria C Pruchnicki; Jerome J Schentag
Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors.
Journal of clinical pharmacology 2006;46(9):968-80.
2006: Sungmin Kiem; Jerome J Schentag
Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia.
Seminars in respiratory and critical care medicine 2006;27(1):51-67.
2005: Gary A Noskin; Robert J Rubin; Jerome J Schentag; Jan A J W Kluytmans; Edwin C Hedblom; Maartje Smulders; Elizabeth Lapetina; Eric Gemmen
The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database.
Archives of internal medicine 2005;165(15):1756-61.
2005: Xiao-Fei Zhou; Linping Zhang; Elaine Tseng; Elizabeth Scott-Ramsay; Jerome J Schentag; Robert A Coburn; Marilyn E Morris
New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(3):321-8.
2004: Pamela A Moise-Broder; George Sakoulas; George Miltiades Eliopoulos; Jerome J Schentag; Alan Forrest; Robert C Moellering
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(12):1700-5.
2004: Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.
Antimicrobial agents and chemotherapy 2004;48(6):2061-8.
2004: Kevin W Broder; Pamela A Moise; Raymond O Schultz; Alan Forrest; Jerome J Schentag
Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis.
Annals of plastic surgery 2004;52(4):385-90.
2004: craig rayner; L M Baddour; Mary C Birmingham; C Norden; Alison K Meagher; Jerome J Schentag
Linezolid in the treatment of osteomyelitis: results of compassionate use experience.
Infection 2004;32(1):8-14.
2004: Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
Clinical pharmacokinetics 2004;43(13):925-42.
2003: Sujata M Bhavnani; Wendy A Callen; Alan Forrest; Kristin K Gilliland; David A Collins; Joseph A Paladino; Jerome J Schentag
Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2003;60(19):1962-70.
2003: Jerome J Schentag; Alison K Meagher; Alan Forrest
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.
The Annals of pharmacotherapy 2003;37(10):1478-88.
2003: Jerome J Schentag; Alison K Meagher; Alan Forrest
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.
The Annals of pharmacotherapy 2003;37(9):1287-98.
2003: Joseph A Paladino; Jenna L Sunderlin; Alan Forrest; Jerome J Schentag
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 2003;52(3):457-63.
2003: P F Smith; Mary C Birmingham; G A Noskin; Alison K Meagher; Alan Forrest; craig rayner; Jerome J Schentag
Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):795-801.
2003: Alison K Meagher; Alan Forrest; craig rayner; Mary C Birmingham; Jerome J Schentag
Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.
Antimicrobial agents and chemotherapy 2003;47(2):548-53.
2003: Edina H Moylett; Susan E Pacheco; Barbara A Brown-Elliott; Tracy R Perry; E Stephen Buescher; Mary C Birmingham; Jerome J Schentag; Joseph F Gimbel; Aaron Apodaca; Margot A Schwartz; Robert M Rakita; Richard J Wallace
Clinical experience with linezolid for the treatment of nocardia infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(3):313-8.
2003: Mary C Birmingham; craig rayner; Alison K Meagher; Susan M Flavin; Donald H Batts; Jerome J Schentag
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(2):159-68.
2003: craig rayner; Alan Forrest; Alison K Meagher; Mary C Birmingham; Jerome J Schentag
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.
Clinical pharmacokinetics 2003;42(15):1411-23.
2002: Pamela A Moise; Alan Forrest; Mary C Birmingham; Jerome J Schentag
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin.
The Journal of antimicrobial chemotherapy 2002;50(6):1017-26.
2002: Robert Wilson; Jerome J Schentag; Peter Ball; Lionel Mandell
A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.
Clinical therapeutics 2002;24(4):639-52.
2002: Joseph A Paladino; Jenna L Sunderlin; Connie S Price; Jerome J Schentag
Economic consequences of antimicrobial resistance.
Surgical infections 2002;3(3):259-67.
2001: Patrick F Smith; CH Ballow; Brent M Booker; Alan Forrest; Jerome J Schentag
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.
Clinical therapeutics 2001;23(8):1231-44.
2001: J D Scott; A Forrest; S Feuerstein; P Fitzpatrick; Jerome J Schentag
Factors associated with postoperative infection.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2001;22(6):347-51.
2001: Jerome J Schentag
Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit.
Critical care medicine 2001;29(4 Suppl):N100-7.
2001: Jerome J Schentag; K K Gilliland; Joseph A Paladino
What have we learned from pharmacokinetic and pharmacodynamic theories?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 1():S39-46.
2001: T R Perry; Jerome J Schentag
Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.
Clinical pharmacokinetics 2001;40(9):685-94.
2000: Pamela A Moise; Jerome J Schentag
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections.
International journal of antimicrobial agents 2000;16 Suppl 1():S31-4.
2000: B Meinl; JM Hyatt; Alan Forrest; S Chodosh; Jerome J Schentag
Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone.
International journal of antimicrobial agents 2000;16(3):273-80.
2000: Pamela A Moise; Alan Forrest; Sujata M Bhavnani; Mary C Birmingham; Jerome J Schentag
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2000;57 Suppl 2():S4-9.
2000: Aileen B Luzier; Alan Forrest; S G Feuerstein; Jerome J Schentag; J L Izzo
Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization.
The American journal of cardiology 2000;86(5):519-23.
2000: Jerome J Schentag
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31 Suppl 2():S40-4.
2000: Pamela A Moise; Mary C Birmingham; Jerome J Schentag
Pharmacokinetics and metabolism of moxifloxacin.
Drugs of today (Barcelona, Spain : 1998) 2000;36(4):229-44.
2000: Jerome J Schentag
Sparfloxacin: a review.
Clinical therapeutics 2000;22(4):372-87; discussion 371.
2000: K E Pickerill; J A Paladino; Jerome J Schentag
Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.
Pharmacotherapy 2000;20(4):417-28.
2000: J Q Tran; CH Ballow; Alan Forrest; JM Hyatt; M F Sands; C A Peloquin; Jerome J Schentag
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
The Journal of antimicrobial chemotherapy 2000;45():9-17.
2000: JM Hyatt; Jerome J Schentag
Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2000;21(1 Suppl):S18-21.
2000: JM Hyatt; Jerome J Schentag
Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2000;21(1 Suppl):S9-11.
1999: Jerome J Schentag
Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1999;56(22 Suppl 3):S21-4.
1999: Jerome J Schentag
Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. Introduction.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1999;56(22 Suppl 3):S3.
1999: R P Rifenburg; Joseph A Paladino; Sujata M Bhavnani; D D Haese; Jerome J Schentag
Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1999;56(21):2217-23.
1999: DE Nix; RA Di Cicco; Ann K Miller; Duane A Boyle; SC Boike; NM Zariffa; Diane K Jorkasky; Jerome J Schentag
The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline.
Journal of clinical pharmacology 1999;39(8):855-65.
1999: V S Highet; Alan Forrest; CH Ballow; Jerome J Schentag
Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
The Journal of antimicrobial chemotherapy 1999;43 Suppl A():55-63.
1999: Mary C Birmingham; R Guarino; A Heller; J H Wilton; A Shah; L Hejmanowski; D E Nix; Jerome J Schentag
Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose.
The Journal of antimicrobial chemotherapy 1999;43 Suppl A():43-8.
1998: Pamela A Moise; Jerome J Schentag
Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.
Current opinion in infectious diseases 1998;11(6):673-80.
1998: LC Strenkoski-Nix; Alan Forrest; Jerome J Schentag; DE Nix
Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
Journal of clinical pharmacology 1998;38(11):1063-71.
1998: Aileen B Luzier; Alan Forrest; M Adelman; FI Hawari; Jerome J Schentag; J L Izzo
Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.
The American journal of cardiology 1998;82(4):465-9.
1998: Jerome J Schentag; LC Strenkoski-Nix; DE Nix; Alan Forrest
Pharmacodynamic interactions of antibiotics alone and in combination.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(1):40-6.
1998: Ronald Jones; CH Ballow; Douglas J Biedenbach; JA Deinhart; Jerome J Schentag
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Diagnostic microbiology and infectious disease 1998;31(3):437-51.
1998: Ronald Jones; CH Ballow; Jerome J Schentag; DM Johnson; JA Deinhart
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Diagnostic microbiology and infectious disease 1998;31(1):313-25.
1998: Jerome J Schentag; JM Hyatt; JR Carr; Joseph A Paladino; Mary C Birmingham; G S Zimmer; TJ Cumbo
Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(5):1204-14.
1998: J K Thomas; Alan Forrest; Sujata M Bhavnani; JM Hyatt; A Cheng; CH Ballow; Jerome J Schentag
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.
Antimicrobial agents and chemotherapy 1998;42(3):521-7.
1997: Mary C Birmingham; J M Hassett; Jerome J Schentag; Joseph A Paladino
Assessing antibacterial pharmacoeconomics in the intensive care unit.
PharmacoEconomics 1997;12(6):637-47.
1997: A Forrest; S Chodosh; Michael A Amantea; D A Collins; Jerome J Schentag
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
The Journal of antimicrobial chemotherapy 1997;40 Suppl A():45-57.
1997: Jerome J Schentag; Mary C Birmingham; J A Paladino; JR Carr; JM Hyatt; Alan Forrest; G S Zimmer; M H Adelman; TJ Cumbo
In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
Seminars in respiratory infections 1997;12(4):278-93.
1997: CH Ballow; Ronald Jones; DM Johnson; JA Deinhart; Jerome J Schentag
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Diagnostic microbiology and infectious disease 1997;29(3):173-86.
1997: DE Nix; J K Thomas; W T Symonds; J M Spivey; JH Wilton; N C Gagliardi; Jerome J Schentag
Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics.
The Annals of pharmacotherapy 1997;31(6):696-703.
1997: JM Hyatt; Aileen B Luzier; Alan Forrest; CH Ballow; Jerome J Schentag
Modeling the response of pneumonia to antimicrobial therapy.
Antimicrobial agents and chemotherapy 1997;41(6):1269-74.
1997: DE Nix; JH Wilton; JM Hyatt; J Thomas; LC Strenkoski-Nix; Alan Forrest; Jerome J Schentag
Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.
Antimicrobial agents and chemotherapy 1997;41(5):1108-14.
1997: JR Carr; P Fitzpatrick; J L Izzo; TJ Cumbo; Mary C Birmingham; Martin H Adelman; Joseph A Paladino; S C Hanson; Jerome J Schentag
Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1997;18(4):255-9.
1996: Joseph A Paladino; G S Zimmer; Jerome J Schentag
The economic potential of dual individualisation methodologies.
PharmacoEconomics 1996;10(6):539-45.
1996: Jerome J Schentag; DE Nix; Alan Forrest; M H Adelman
AUIC--the universal parameter within the constraint of a reasonable dosing interval.
The Annals of pharmacotherapy 1996;30(9):1029-31.
1996: R P Rifenburg; J A Paladino; S C Hanson; J A Tuttle; Jerome J Schentag
Benchmark analysis of strategies hospitals use to control antimicrobial expenditures.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1996;53(17):2054-62.
1995: Jerome J Schentag; J A Paladino; Mary C Birmingham; G Zimmer; J R Carr; S C Hanson
Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 1995;11(5):203-10.
1995: JM Hyatt; DE Nix; C W Stratton; Jerome J Schentag
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1995;39(8):1711-6.
1995: DE Nix; Jerome J Schentag
Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
Diagnostic microbiology and infectious disease 1995;22(1-2):71-6.
1995: D J Kazierad; G J Wojcik; DE Nix; A L Goldfarb; Jerome J Schentag
The effect of verapamil on the nephrotoxic potential of gentamicin as measured by urinary enzyme excretion in healthy volunteers.
Journal of clinical pharmacology 1995;35(2):196-201.
1995: JM Hyatt; P S McKinnon; G S Zimmer; Jerome J Schentag
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
Clinical pharmacokinetics 1995;28(2):143-60.
1994: G W Amsden; T F Goss; N J Harrison; D T D'Andrea; Jerome J Schentag
Pharmacodynamics of bolus famotidine versus infused cimetidine, ranitidine, and famotidine.
Journal of clinical pharmacology 1994;34(12):1191-8.
1994: JM Hyatt; DE Nix; Jerome J Schentag
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
Antimicrobial agents and chemotherapy 1994;38(12):2730-7.
1994: Joseph A Paladino; M A Rainstein; D J Serrianne; J E Przylucki; L S Welage; M L Collura; Jerome J Schentag
Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery.
Pharmacotherapy 1994;14(6):734-9.
1994: T F Goss; Alan Forrest; DE Nix; CH Ballow; Mary C Birmingham; T J Cumbo; Jerome J Schentag
Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.
The Annals of pharmacotherapy 1994;28(7-8):863-8.
1994: K Huh; J H Wilton; DE Nix; Jerome J Schentag
Structures and biological activities of tobramycin-ticarcillin adducts.
Journal of pharmaceutical sciences 1994;83(6):763-7.
1994: R C Li; D E Nix; Jerome J Schentag
Interaction between ciprofloxacin and metal cations: its influence on physicochemical characteristics and antibacterial activity.
Pharmaceutical research 1994;11(6):917-20.
1993: Mary C Birmingham; DE Nix; T J Cumbo; D A Collins; P B Wels; Jerome J Schentag
The development of a bedside algorithm capable of targeting anti-endotoxins to the responder subpopulations.
Therapeutic drug monitoring 1993;15(6):503-9.
1993: C Alioth; Robert A Blum; D T D'Andrea; G M Kochak; L Teng; B A Ziehmer; Jerome J Schentag; K K Chan
Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers.
Pharmaceutical research 1993;10(11):1688-92.
1993: Alan Forrest; DE Nix; CH Ballow; T F Goss; Mary C Birmingham; Jerome J Schentag
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
Antimicrobial agents and chemotherapy 1993;37(5):1073-81.
1993: Alan Forrest; CH Ballow; DE Nix; Mary C Birmingham; Jerome J Schentag
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
Antimicrobial agents and chemotherapy 1993;37(5):1065-72.
1993: Jerome J Schentag; T F Goss
Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease.
American journal of hospital pharmacy 1993;50(4 Suppl 1):S7-10.
1993: Jerome J Schentag; CH Ballow; A L Fritz; J A Paladino; J D Williams; T J Cumbo; R V Ali; V A Galletta; M B Gutfeld; M H Adelman
Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory.
Diagnostic microbiology and infectious disease 1993;16(3):255-64.
1993: R C Li; Jerome J Schentag; DE Nix
The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions.
Antimicrobial agents and chemotherapy 1993;37(3):523-31.
1993: R C Li; DE Nix; Jerome J Schentag
New turbidimetric assay for quantitation of viable bacterial densities.
Antimicrobial agents and chemotherapy 1993;37(2):371-4.
1992: A Luzier; T F Goss; T J Cumbo; Jerome J Schentag
Mathematical examination of dual individualization principles. (III): Development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients.
The Annals of pharmacotherapy 1992;26(11):1358-65.
1992: M E Lebsack; DE Nix; B Ryerson; Roger Toothaker; L Welage; A M Norman; Jerome J Schentag; Allen J Sedman
Effect of gastric acidity on enoxacin absorption.
Clinical pharmacology and therapeutics 1992;52(3):252-6.
1992: M C Chapelsky; DE Nix; J C Cavanaugh; J H Wilton; A Norman; Jerome J Schentag
Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers.
Drug safety : an international journal of medical toxicology and drug experience 1992;7(4):304-9.
1992: Jerome J Schentag; T F Goss
Quinolone pharmacokinetics in the elderly.
The American journal of medicine 1992;92(4A):33S-37S.
1992: DE Nix; J H Wilton; N Velasquez; J L Budny; H B Lassman; P Mitchell; K Divan; Jerome J Schentag
Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges.
The Journal of antimicrobial chemotherapy 1992;29 Suppl A():51-7.
1992: CH Ballow; Jerome J Schentag
Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group.
Diagnostic microbiology and infectious disease 1992;15(2 Suppl):37S-42S.
1992: DE Nix; J M Spivey; A Norman; Jerome J Schentag
Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses.
The Annals of pharmacotherapy 1992;26(1):8-10.
1991: Joseph A Paladino; H E Sperry; J M Backes; J A Gelber; D J Serrianne; T J Cumbo; Jerome J Schentag
Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.
The American journal of medicine 1991;91(5):462-70.
1991: Jerome J Schentag; DE Nix; M H Adelman
Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
DICP : the annals of pharmacotherapy 1991;25(10):1050-7.
1991: DE Nix; S D Goodwin; C A Peloquin; D L Rotella; Jerome J Schentag
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.
Antimicrobial agents and chemotherapy 1991;35(10):1953-9.
1991: DE Nix; S D Goodwin; C A Peloquin; D L Rotella; Jerome J Schentag
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning.
Antimicrobial agents and chemotherapy 1991;35(10):1947-52.
1991: S C Piscitelli; T F Goss; J H Wilton; D T D'Andrea; H Goldstein; Jerome J Schentag
Effects of ranitidine and sucralfate on ketoconazole bioavailability.
Antimicrobial agents and chemotherapy 1991;35(9):1765-71.
1991: C A Peloquin; T J Cumbo; Jerome J Schentag
Kinetics and dynamics of tobramycin action in patients with bacteriuria given single doses.
Antimicrobial agents and chemotherapy 1991;35(6):1191-5.
1991: Robert A Blum; D T D'Andrea; B M Florentino; J H Wilton; D M Hilligoss; M J Gardner; E B Henry; H Goldstein; Jerome J Schentag
Increased gastric pH and the bioavailability of fluconazole and ketoconazole.
Annals of internal medicine 1991;114(9):755-7.
1991: Robert A Blum; J H Wilton; D M Hilligoss; M J Gardner; E B Henry; N J Harrison; Jerome J Schentag
Effect of fluconazole on the disposition of phenytoin.
Clinical pharmacology and therapeutics 1991;49(4):420-5.
1991: Jerome J Schentag
Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials.
Pharmacotherapy 1991;11(1):2-19.
1990: Lynda S Welage; M T Borin; J H Wilton; L G Hejmanowski; P B Wels; Jerome J Schentag
Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole.
Antimicrobial agents and chemotherapy 1990;34(12):2369-74.
1990: Robert A Blum; R W Schultz; Jerome J Schentag
Pharmacokinetics of lomefloxacin in renally compromised patients.
Antimicrobial agents and chemotherapy 1990;34(12):2364-8.
1990: C E Haas; DE Nix; Jerome J Schentag
In vitro selection of resistant Helicobacter pylori.
Antimicrobial agents and chemotherapy 1990;34(9):1637-41.
1990: Jerome J Schentag
Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
Scandinavian journal of infectious diseases. Supplementum 1990;74():218-34.
1989: DE Nix; W A Watson; M E Lener; R W Frost; G Krol; H Goldstein; J Lettieri; Jerome J Schentag
Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.
Clinical pharmacology and therapeutics 1989;46(6):700-5.
1989: C A Peloquin; T J Cumbo; DE Nix; M F Sands; Jerome J Schentag
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Archives of internal medicine 1989;149(10):2269-73.
1989: Robert A Blum; R K Kohli; N J Harrison; Jerome J Schentag
Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
Antimicrobial agents and chemotherapy 1989;33(9):1470-6.
1989: DE Nix; A Norman; Jerome J Schentag
Effect of lomefloxacin on theophylline pharmacokinetics.
Antimicrobial agents and chemotherapy 1989;33(7):1006-8.
1989: Lynda S Welage; L G Hejmanowski; J H Wilton; Cynthia A Walawander; D Rigan; J S Williams; Jerome J Schentag
Comparison of N-methylthiotetrazole dispositions in healthy volunteers following single intravenous doses of moxalactam, cefoperazone, and cefotetan.
Antimicrobial agents and chemotherapy 1989;33(6):857-61.
1989: T H Grasela; Jerome J Schentag; Allen J Sedman; J H Wilton; D J Thomas; R W Schultz; M E Lebsack; A W Kinkel
Inhibition of enoxacin absorption by antacids or ranitidine.
Antimicrobial agents and chemotherapy 1989;33(5):615-7.
1989: V X Nguyen; DE Nix; S Gillikin; Jerome J Schentag
Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.
Antimicrobial agents and chemotherapy 1989;33(4):434-6.
1989: Joseph Dipiro; Lynda S Welage; B A Levine; P E Wing; J A Stanfield; H V Gaskill; D S Scarfoni; Jerome J Schentag; T A Bowden; J S Williams
Single-dose cefmetazole versus multiple dose cefoxitin for prophylaxis in abdominal surgery.
The Journal of antimicrobial chemotherapy 1989;23 Suppl D():71-7.
1989: T H Grasela; Jerome J Schentag; S J Boekenoogen; K D Crist; W L Lowes; B L Lum
A clinical pharmacy-oriented drug surveillance network: results of a nationwide antibiotic utilization review of bacterial pneumonia--1987.
DICP : the annals of pharmacotherapy 1989;23(2):162-70.
1989: T H Grasela; Cynthia A Walawander; Lynda S Welage; P E Wing; D J Scarafoni; J W Caldwell; J K Noguchi; Jerome J Schentag
Prospective surveillance of antibiotic-associated coagulopathy in 970 patients.
Pharmacotherapy 1989;9(3):158-64.
1989: S H Parpia; DE Nix; L G Hejmanowski; H R Goldstein; J H Wilton; Jerome J Schentag
Sucralfate reduces the gastrointestinal absorption of norfloxacin.
Antimicrobial agents and chemotherapy 1989;33(1):99-102.
1989: Jerome J Schentag
Clinical significance of antibiotic tissue penetration.
Clinical pharmacokinetics 1989;16 Suppl 1():25-31.
1988: Jerome J Schentag; Lynda S Welage; J S Williams; J H Wilton; M H Adelman; D Rigan; T H Grasela
Kinetics and action of N-methylthiotetrazole in volunteers and patients. Population-based clinical comparisons of antibiotics with and without this moiety.
American journal of surgery 1988;155(5A):40-4.
1988: D L Rescott; DE Nix; P Holden; Jerome J Schentag
Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli.
Antimicrobial agents and chemotherapy 1988;32(4):450-3.
1988: DE Nix; Jerome J Schentag
The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.
Journal of clinical pharmacology 1988;28(2):169-78.
1988: DE Nix; R W Schultz; R W Frost; Allen J Sedman; D J Thomas; A W Kinkel; Jerome J Schentag
The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin.
The Journal of antimicrobial chemotherapy 1988;21 Suppl B():87-95.
1987: T H Grasela; Jerome J Schentag
A clinical pharmacy-oriented drug surveillance network: I. Program description.
Drug intelligence & clinical pharmacy 1987;21(11):902-8.
1987: D E Nix; M F Sands; C A Peloquin; A J Vari; T J Cumbo; J W Vance; J E Fracasso; Jerome J Schentag
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
The American journal of medicine 1987;82(4A):352-6.
1987: D E Nix; T J Cumbo; P Kuritzky; J M DeVito; Jerome J Schentag
Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics.
The American journal of medicine 1987;82(4A):146-53.
1987: DE Nix; J M DeVito; M A Whitbread; Jerome J Schentag
Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green.
The Journal of antimicrobial chemotherapy 1987;19(2):263-9.
1987: Jerome J Schentag; Lynda S Welage; T H Grasela; M H Adelman
Determinants of antibiotic-associated hypoprothrombinemia.
Pharmacotherapy 1987;7(3):80-6.
1986: D J Swanson; C DeAngelis; I L Smith; Jerome J Schentag
Degradation kinetics of imipenem in normal saline and in human serum.
Antimicrobial agents and chemotherapy 1986;29(5):936-7.
1985: N E Winslade; I L Smith; G W Simons; D J Swanson; A Vigano; P B Wels; Jerome J Schentag
Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis.
Reviews of infectious diseases 1985;7 Suppl 4():S716-23.
1985: Jerome J Schentag; A J Vari; N E Winslade; D J Swanson; I L Smith; G W Simons; A Vigano
Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
The American journal of medicine 1985;78(2A):34-41.
1985: D P Reitberg; I L Smith; S J Love; H M Lewin; Jerome J Schentag
A rapid, universal TI-59 model-independent pharmacokinetic analysis program based on statistical moment theory.
Drug intelligence & clinical pharmacy 1985;19(2):125-34.
1985: Jerome J Schentag; D J Swanson; I L Smith
Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics.
The Journal of antimicrobial chemotherapy 1985;15 Suppl A():47-57.
1985: J G Baxter; D A Marble; L R Whitfield; P B Wels; P Walczak; Jerome J Schentag
Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin.
Annals of surgery 1985;201(1):96-102.
1984: Jerome J Schentag; I L Smith; D J Swanson; C DeAngelis; J E Fracasso; A Vari; J W Vance
Role for dual individualization with cefmenoxime.
The American journal of medicine 1984;77(6A):43-50.
1984: Jerome J Schentag; D P Reitberg; T J Cumbo
Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia.
The American journal of medicine 1984;77(6A):34-42.
1984: J M DeVito; DE Nix; Jerome J Schentag
No false "Hemoccult" reaction with ranitidine.
The New England journal of medicine 1984;311(13):861.
1984: D P Reitberg; T J Cumbo; Jerome J Schentag
Cefmenoxime in the treatment of nosocomial pneumonias in critical care patients.
The Journal of antimicrobial chemotherapy 1984;14(1):81-91.
1984: D P Reitberg; T J Cumbo; I L Smith; Jerome J Schentag
Effect of protein binding on cefmenoxime steady-state kinetics in critical patients.
Clinical pharmacology and therapeutics 1984;35(1):64-73.
1983: D J Swanson; D P Reitberg; I L Smith; P B Wels; Jerome J Schentag
Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.
Journal of pharmacokinetics and biopharmaceutics 1983;11(4):337-53.
1983: Jerome J Schentag; P B Wels; D P Reitberg; P Walczak; J H Van Tyle; R J Lascola
A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis.
Annals of surgery 1983;198(1):35-41.